Clinical Trials on Non-Alcoholic Steatohepatitis(NASH)

Total 1305 results

Regeneron Pharmaceuticals

Recruiting

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

Non-alcoholic Steatohepatitis (NASH) | Metabolic Dysfunction Associated Steatohepatitis (MASH)

United States, Korea, Republic of, Puerto Rico, Japan
Aligos Therapeutics

Recruiting

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) (HERALD)

Nonalcoholic Steatohepatitis | NASH | MASH | Metabolic Dysfunction-Associated Steatohepatitis

United States
Corcept Therapeutics

Recruiting

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH)

United States, Puerto Rico
Corcept Therapeutics

Recruiting

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH)

United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR)

Non-alcoholic Steatohepatitis (NASH)

Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
Immuron Ltd.

Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis (NASH)

United States, Australia, Israel
Haisco Pharmaceutical Group Co., Ltd.

Recruiting

To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .

Non-Alcoholic Steatohepatitis (NASH)

China
AstraZeneca

Active, not recruiting

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Non-alcoholic Steatohepatitis (NASH)

United States
Zhejiang Medicine Co., Ltd.
The Affiliated Hospital of Hangzhou Normal University; R&G Pharma Studies Co...

Completed

Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis

NASH (Non-Alcoholic Steatohepatitis)

China
Regeneron Pharmaceuticals

Terminated

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis (NASH)

Brazil, United States, Puerto Rico, Korea, Republic of, Mexico
NorthSea Therapeutics B.V.

Active, not recruiting

A Phase 2b Study of Icosabutate in Fatty Liver Disease (ICONA)

Non Alcoholic Steatohepatitis (NASH)

United States, Puerto Rico
Hepanova Inc.

Unknown

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

Non-Alcoholic Steatohepatitis (NASH)

United States
University of Palermo

Unknown

Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis

•Non-alcoholic Steatohepatitis (NASH)

Italy
Pfizer

Completed

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

Non-Alcoholic Steatohepatitis(NASH)

United States
Eccogene

Recruiting

FTIH of ECC4703 in Healthy Volunteers

Non-alcoholic Steatohepatitis (NASH)

United States
Guangdong Raynovent Biotech Co., Ltd

Completed

Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH)

China
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Non-alcoholic Steatohepatitis NASH

United Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
Hoffmann-La Roche

Completed

Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH)

France
University of Zurich

Completed

Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D

Non-alcoholic Steatohepatitis (NASH)

Switzerland
Can-Fite BioPharma

Completed

A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

Non-alcoholic Steatohepatitis (NASH)

Israel
Boehringer Ingelheim

Completed

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Non-alcoholic Steatohepatitis (NASH)

United States, Spain, Korea, Republic of, United Kingdom, Australia, Canada, Singapore, Germany, Italy, Malaysia, China, France, Japan, Netherlands, Taiwan, Austria, Israel, New Zealand, Poland, Hong Kong, Belgium, Czechia, Greece, Hu... and more
Intercept Pharmaceuticals

Terminated

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Non Alcoholic Steatohepatitis (NASH)

United States, Finland, France, Spain, United Kingdom, Israel, Austria, Italy, Denmark, Germany, Belgium, Switzerland, Puerto Rico, Poland, Australia, Sweden, Serbia, New Zealand, Canada, Hungary, Portugal
Inventiva Pharma

Completed

Phase 2b Study in NASH to Assess IVA337 (NATIVE)

Non-Alcoholic Steatohepatitis (NASH)

United States, Spain, United Kingdom, France, Belgium, Austria, Switzerland, Australia, Germany, Slovenia, Bulgaria, Canada, Czechia, Italy, Mauritius, Poland
Genfit
Premier Research Group plc; Naturalpha

Completed

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH)

United States, Belgium, France, Germany, Italy, Netherlands, Romania, Spain, United Kingdom
University of Minnesota

Recruiting

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
Galectin Therapeutics Inc.

Completed

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Non-Alcoholic Steatohepatitis (NASH)

United States
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Sinew Pharma Inc.

Not yet recruiting

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis
Kafrelsheikh University

Completed

Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients

Nonalcoholic Steatohepatitis (NASH)

Egypt
Can-Fite BioPharma

Recruiting

Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

Israel, Bosnia and Herzegovina, Bulgaria, Moldova, Republic of, Romania, Serbia
Gehad Abd Elaziz Mhmoud Ahmad

Unknown

Non Alcoholic Steatohepatitis in Relation to Visceral and Subcutaneous Fat

NASH - Nonalcoholic Steatohepatitis
Milton S. Hershey Medical Center

Withdrawn

NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal (NASH-FITTER)

NASH - Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease | Non Alcoholic Steatohepatitis
University of Illinois at Chicago

Terminated

Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH) | Hepatic Steatosis

United States
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Non-alcoholic Steatohepatitis (NASH)

Germany
Shupei Li

Recruiting

A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar

NASH

China
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

NASH

Japan
Cirius Therapeutics, Inc.
Chiltern International Inc.

Completed

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH (EMMINENCE)

Non-alcoholic Fatty Liver Disease | NASH - Nonalcoholic Steatohepatitis | Non-alcoholic Steatohepatitis

United States
AstraZeneca
Parexel

Completed

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Non-alcoholic Steatohepatitis (NASH)

United States
Axcella Health, Inc

Recruiting

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Non Alcoholic Steatohepatitis (NASH)

United States, Canada, United Kingdom, Australia, France, Poland, Puerto Rico
Milton S. Hershey Medical Center

Not yet recruiting

Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD (ENLIGHTEN)

Liver Diseases | NASH - Nonalcoholic Steatohepatitis | NASH
Instituto de Investigación Marqués de Valdecilla

Recruiting

Efficacy and Safety of Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy in Obese Subjects With NASH (TESLA-NASH)

Non-alcoholic Steatohepatitis (NASH)

Spain
Milton S. Hershey Medical Center

Recruiting

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis

Exercise | NASH - Nonalcoholic Steatohepatitis | NASH | Liver

United States
Bambino Gesù Hospital and Research Institute

Completed

DHA and Vitamin D in Children With Biopsy-proven NAFLD (VitD_DHA)

NAFLD | Non Alcoholic Steatohepatitis (NASH)

Italy
Humanity and Health Research Centre

Recruiting

Longitudinal Observational Study Of Chinese With NAFLD/NASH

Non-Alcoholic Fatty Liver Disease (NAFLD) | Non-Alcoholic Steatohepatitis (NASH)

Hong Kong
University of Alabama at Birmingham
AstraZeneca

Terminated

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

United States
Chinese University of Hong Kong

Not yet recruiting

Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment

Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

Hong Kong
Akero Therapeutics, Inc

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NASH With Fibrosis | MASH With Fibrosis

United States, Canada, Puerto Rico, Australia, India, France, Italy, Poland, Spain
University of Roma La Sapienza
Göteborg University

Completed

Gut Microbiota and Modulation of Liver Damage in NAFLD

Obesity | Non-alcoholic Steatohepatitis (NASH) | Simple Steatosis (SS)

Italy
Instituto de Investigación Marqués de Valdecilla

Unknown

Endoscopic Bariatric Therapy in NASH Cirrhosis (ETHIC)

Non-alcoholic Steatohepatitis (NASH)
Novartis Pharmaceuticals

Terminated

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. (ELIVATE)

Non Alcoholic Steatohepatitis (NASH)

United States, South Africa, Spain, Germany, Italy, Taiwan, Canada, Korea, Republic of, Singapore, Bulgaria, Estonia, Mexico, Japan, Denmark, United Kingdom, Colombia, Brazil, Belgium, Russian Federation, Puerto Rico, Chile, Argen... and more

Clinical Trials on Non-Alcoholic Steatohepatitis(NASH)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations